Novavax, Inc. NVAX shares are trading higher by 8.4% at $242.67 on continued strength after the company on Wednesday announced an agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine.
Novavax shares are trading higher by 32.5% over the past five sessions amid ongoing COVID-19 delta variant concerns, which have lifted vaccine stocks.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly-owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.
Novavax has a 52-week high of $331.68 and a 52-week low of $76.59.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
